NRIX - Nurix Therapeutics Inc
Nurix Therapeutics Inc Logo

NRIX - Nurix Therapeutics Inc

https://www.nurixtx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.

52W High
$29.56
52W Low
$8.18
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.10
Valuation
As of 2025-05-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.35
EV/Revenue (<3 favorable)
3.66
P/S (TTM) (<3 favorable)
8.57
P/B (<3 favorable)
1.69
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.43%
Institutions (25–75% balanced)
115.02%
Shares Outstanding
76,449,000
Float
61,464,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-05-31 (Overview)
Revenue (TTM)
88,381,000
Gross Profit (TTM)
-182,083,008
EPS (TTM)
-2.60
Profit Margin (>10% good)
-2.35%
Operating Margin (TTM) (higher better)
-1.10%
ROE (TTM) (>15% strong)
-0.51%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
2.64
Momentum
Bearish momentum
Value
-0.4867
Previous
-0.5745
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025